Savill J, Mitchell M, Wood D, Krikler D M
Br Heart J. 1985 Sep;54(3):248-50. doi: 10.1136/hrt.54.3.248.
In 25 outpatients taking digoxin for chronic atrial fibrillation (established for at least six months) a prospective study identified only one case in which rapid availability of the results of a plasma digoxin assay altered the dose which had already been selected on the basis of simple clinical assessment. No patient received more than 375 micrograms digoxin per day and none showed clinical evidence of toxicity even though seven had renal impairment. Six other patients had poorly controlled ventricular rates requiring larger doses of digoxin, but even in these patients the dose could be selected on clinical grounds alone. Despite the availability of a very rapid fluorescence polarisation immunoassay for digoxin, simple but careful clinical monitoring is an adequate basis for the selection of a suitable dose in most patients taking digoxin for atrial fibrillation.
在25名因慢性心房颤动(病程至少6个月)而服用地高辛的门诊患者中,一项前瞻性研究仅发现1例血浆地高辛检测结果快速可得的情况改变了根据简单临床评估已选定的剂量。没有患者每天服用超过375微克地高辛,即使7例患者有肾功能损害,也没有患者出现中毒的临床证据。另外6例患者心室率控制不佳,需要更大剂量的地高辛,但即使在这些患者中,仅根据临床情况也可选定剂量。尽管有非常快速的地高辛荧光偏振免疫测定法,但对于大多数因心房颤动服用地高辛的患者而言,简单而仔细的临床监测是选择合适剂量的充分依据。